© 2023 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#integrase inhibitor

AbbVie’s Viekira Is Likely Safe for Kidneys in Those With HIV and Hep C

A recent study analyzed kidney parameters among those with HIV who were treated for hep C with the regimen.

FDA Approves Gilead’s Single-Tablet HIV Regimen Biktarvy

The once-daily regimen includes the integrase inhibitor bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).

Primary Predictor of Immune Recovery Is CD4 Count at Start of HIV Treatment

Starting treatment within four months of infection also predicted a better resurgence of CD4 cells.

DHHS Guidelines: Return of ‘Hit Hard, Hit Early’

The U.S. DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents has come nearly full circle...

H1N1, Latent Reservoirs and ViiV: 2009 in Review

In honor of World AIDS Day, AIDSmeds highlights the year’s top treatment stories.

ICAAC: Once-Daily Isentress as Good as Twice-Daily?

People who switched from a protease inhibitor (PI) to Isentress (raltegravir) did well regardless of whether they switched to a once-daily o...
Advertisement

Hep uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy

Manage

Hep uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.